Jueves 21 de Junio 2018

St. Jude Medical Announces Data to be Presented as Late-Breaking Clinical Trials and Highlights Its Latest Cardiovascular Portfolio at the 2016 TCT Conference

Data presentations and multiple product releases demonstrate the
company’s commitment to transforming the treatment of cardiovascular
disease


ST. PAUL, Minn.–(BUSINESS WIRE)–St. Jude Medical, Inc. (NYSE:STJ), a global medical device company,
announced today that it will have new data featured during late-breaking
clinical trial presentations at the upcoming 2016
Transcatheter Cardiovascular Therapeutics
educational meeting in
Washington, D.C., October 29 – November 2. Throughout the congress, the
company will also feature its latest cardiovascular innovations,
including PressureWire™ X guidewire, the latest generation of the
pioneering PressureWire guidewire system; structural heart solutions and
the CardioMEMS™ HF System.

Three late-breaking or first report investigation sessions and one oral
abstract presentation will highlight data from St. Jude Medical
advancements in vascular and structural heart technologies.

  • A comparison of stent visualization technologies for use during
    percutaneous coronary intervention (PCI) – Data from the first
    randomized clinical trial to compare OCT-guided, IVUS-guided and
    angiography-guided PCI

The session: “ILUMIEN III (OPTIMIZE PCI): A Prospective, Randomized
Trial of OCT-Guided vs. IVUS-Guided vs. Angio-Guided Stent Implantation
in Patients with Coronary Artery Disease,” will be presented by Dr. Ziad
A. Ali, associate director of translational medicine at the Center for
Interventional Vascular Therapy at Columbia University Medical Center in
New York at 9 a.m. on Sunday, October 30. This is the first
late-breaking clinical trial presentation of TCT 2016.

  • Final long term results from the RESPECT trial, comparing recurrent
    stroke in patients with the AMPLATZER™ PFO closure device to
    contemporary medical management

The session: “RESPECT: Final Long-Term Outcomes from a Prospective,
Randomized Trial of PFO Closure in Patients with Cryptogenic Stroke,”
will be presented by Dr. David Thaler, neurologist-in-chief at Tufts
Medical Center and chairman of the Department of Neurology at Tufts
University School of Medicine in Boston, at 12:15 p.m. on Tuesday,
November 1.

Previous results observed a stroke reduction across the totality of
analyses with rates ranging from 51-73 percent.

  • Initial data from the largest, prospective evaluation of the
    AMPLATZER™ Amulet™ LAA occluder device, designed to seal the left
    atrial appendage to prevent stroke in patients with non-valvular
    atrial fibrillation

The session: “AMULET OBSERVATIONAL STUDY: Multicenter, Prospective,
Registry Results with a Left Atrial Appendage Closure Device for Stroke
Prevention in Patients with Atrial Fibrillation,” will be presented by
Dr. David Hildick-Smith, cardiologist at Brighton & Sussex University
Hospitals in the UK, at 9:40 a.m. on Wednesday, November 2.

Leading interventional cardiologists will also be on hand to demonstrate
the OPTIS™ integrated system from 10-11 a.m. and from 2-3 p.m. each day
during exhibit hours (Sunday, Oct. 30, Monday, October 31 and Tuesday,
November 1).

Additionally, on Sunday, October 31, St. Jude Medical is sponsoring a
TCT satellite symposium, “Interventional management of complex patients,
cutting edge technologies for the advanced interventionalist.” For more
information about this event, visit: http://www.crf.org/tct/agenda/satellite-programs.

About St. Jude Medical

St. Jude Medical is a leading global medical device manufacturer and is
dedicated to transforming the treatment of some of the world’s most
expensive epidemic diseases. The company does this by developing
cost-effective medical technologies that save and improve lives of
patients around the world. Headquartered in St. Paul, Minn., St. Jude
Medical has five major areas of focus that include heart failure, atrial
fibrillation, neuromodulation, traditional cardiac rhythm management,
and cardiovascular. For more information, please visit sjm.com
or follow us on Twitter @SJM_Media.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 that involve
risks and uncertainties. Such forward-looking statements include the
expectations, plans and prospects for the company, including potential
clinical successes, reimbursement strategies, anticipated regulatory
approvals and future product launches, and projected revenues, margins,
earnings and market shares. The statements made by the company are based
upon management’s current expectations and are subject to certain risks
and uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. These risks and
uncertainties include market conditions and other factors beyond the
company’s control and the risk factors and other cautionary statements
described in the company’s filings with the SEC, including those
described in the Risk Factors and Cautionary Statements sections of the
company’s Annual Report on Form 10-K for the fiscal year ended January
2, 2016 and Quarterly Report on Form 10-Q for the fiscal quarter ended
July 2, 2016. The company does not intend to update these statements and
undertakes no duty to any person to provide any such update under any
circumstance.

Contacts

St. Jude Medical, Inc.
J.C. Weigelt, 651-756-4347
Investor
Relations
jweigelt@sjm.com
or
Gina
O’Connell, 651-756-3380
Media Relations
Goconnell02@sjm.com